Study did not meet primary endpoints of mean change in low luminance visual acuity (LLVA) and geographic atrophy (GA) progression
Categorical improvement in LLVA, with >15% of elamipretide-treated patients gaining 2+ lines of vision at Week 48
Elamipretide demonstrated enhanced ellipsoid zone preservation through reduction of progressive attenuation, an important indicator of photoreceptor loss.
Company to host conference call and webcast today at 8:30 a.m. ET
Conference Call Information
Stealth will host a conference call and webcast today at 8:30 am ET to discuss the ReCLAIM-2 trial. The call can be accessed by dialing 1-877-407-0989 (toll free) or 1-201-389-0921 (international) and referencing conference ID 13729736. A live audio webcast of the event can be accessed by visiting the Investors & News section of Stealth's Investor website, https://investor.stealthbt.com/. A replay of the webcast will be archived on Stealth's website for 30 days following the event.
https://finance.yahoo.com/news/stealth-biotherapeutics-announces-data-reclaim-113000750.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.